#adcetris

Antibody-drug conjugates have emerged as a promising class of therapeutics in the field of oncology. By combining the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic drugs, Antibody-drug conjugates offer a targeted approach to cancer treatment. In this blog, we will explore the current and future landscape of Antibody-drug conjugates in oncology, including…

Top Pharma News of the Week – September 24th

All The Most Important Pharmaceutical News Stories Of The Week – September 2018 – Week # 4 FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis

September 20, 2018

ACADIA Pharmaceuticals Inc. has announced that the FDA has completed a postmarketing review and…

Top Pharma News of the Week – March 26th

All The Most Important Pharmaceutical News Stories Of The Week – March 2018 – Week #4 Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma

March 20, 2018

Seattle Genetics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS…

All The Most Important Pharmaceutical News Stories Of The Week – January 2018 – Week #5 Amgen Reports Aimovig™ (Erenumab) Met All Primary and Secondary Endpoints in Unique Phase 3b Study in Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments

January 22, 2018

Amgen has announced positive results from the Phase 3b LIBERTY study assessing the efficacy and safety of…